Novel Biomarkers Assistance to Predict Rejection after Stem Cell Transplantation Found

The most recent study by Dr. Sophie Paczesny yet others at MUSC Hollings Cancer Center revealed a brand new type of immune cell biomarkers, which might reveal which people are most vulnerable to graft-versus-host disease (GVHD). This research was printed on Science Translational Medicine.

Paczesny, director from the Department of Microbiology and Immunology at MUSC, described: “Allogeneic HSCT continues to be the only effective therapy for leukemia. In HSCT, donor-matched cells are injected in to the bloodstream of diseased patients and finally go into the bone marrow. A few of these cells differentiate into immune cells which help eliminate residual leukemia cancer cells that aren’t wiped out by chemotherapy. However, some donors’ immune cells may attack a person’s own healthy tissue simultaneously, that is known as graft-versus-host disease.”

GVHD affects as much as 50% of patients undergoing HSCT and may manifest in multiple organs. About one-third of individuals with GVHD experience localized effects within the gastrointestinal tract (GI-GVHD), posing the greatest chance of dying.

This phenomenon was further explained Paczesny. “For leukemia patients, the donor cells you provide have different biological or antigenic characteristics compared to recipients. This is the way these immune cells recognize leukemia and destroy leukemia. However, these antigens will also be contained in normal tissues particularly in body regions most abundant in microbiota (like the gut). Therefore, donor immune cells break out there and signs and symptoms are hardest to deal with.”

Bone marrow stem cells are known as pluripotent stem cells, meaning they are able to mature into various sorts of cells. Including red and white-colored bloodstream cells along with other immune cell types accountable for balancing immunity and tolerance, for example dendritic cells and T cells.

Dendritic cells can exchange information with T cells through antigen molecules presented by MHC complexes around the cell surface. T cells are activated in recognition of “non-self” antigens after which play a vital role in triggering your body’s other defense systems against foreign invaders, which might include transplanted cells from various hosts.

Previous work in the Paczesny laboratory has proven that immune cell signaling pathways in GI-GVHD increase the amount of “hyperactivated” pathogenic T cells (Th17 cells) within the bloodstream of those patients. The existence of these aggressive T cells was connected with lower survival when compared with patients missing GVHD or with milder types of GVHD within the skin. These cells will also be unique within their capability to induce ICOS, a category of T cell signaling coreceptors.

Paczesny stated. “We are attempting to understand in which the activation of those T cells originates from. What antigen-presenting cells are?”

Since ICOS ligands are on the the surface of antigen-presenting cells, for example dendritic cells, they may be easily detected using existing technologies, for example flow cytometry, which could scan the bloodstream for exterior labeling on cells. In this manner, those who develop GI-GVHD signs and symptoms after treatment might be flagged out.

Paczesny’s group demonstrated that GI-GVHD patients had elevated amounts of dendritic cells expressing ICOS ligands (particularly a population known as plasmacytoid dendritic cells) when compared with controls. Crucially, patients rich in amounts of these cells were built with a reduced three-year survival when compared with lower levels of cells.

Dr. Djamilatou Adom, a postdoctoral investigator dealing with Paczesny, further investigated the function of ICOS signaling using rodents in GI-GVHD. First, they demonstrated that genetic abrogation of ICOS ligand production before transplantation of donor mouse bone marrow cells into recipient rodents could safeguard recipient rodents from GvHD related dying. Additionally, they used “humanized” rodents having a non-functional defense mechanisms and located that transplanting plasmacytoid dendritic cells expressing human ICOS ligands in to these rodents (whose own bone marrow continues to be destroyed by radiation) led to elevated amounts of Th17 cells within GVHD.

The participation of plasmacytoid dendritic cells (pDCs) in GVHD is definitely an interesting finding, Paczesny states. “If these cells aren’t stimulated, they can be regarded as tolerogenic. Quite simply, they are able to reduce the seriousness of GVHD. However, when they activate T cells, for instance by binding ICOS activation , they be toxic and could drive the introduction of GVHD.”